An immediate or early invasive strategy in non-ST-elevation acute coronary syndrome: The OPTIMA-2 randomized controlled trial
- Resource Type
- Authors
- Maarten A. Vink; Freek W.A. Verheugt; Ton Slagboom; Robert K. Riezebos; Robbert J. de Winter; Jean-Paul R. Herrman; Nicola S. Vos; Jan G.P. Tijssen; Erik F. J. Oosterwerff; Giovanni Amoroso; Nick D. Fagel; Mark S. Patterson; René J. van der Schaaf
- Source
- American heart journal, 234, 42-50. Mosby Inc.
- Subject
- Male
Ticagrelor
Acute coronary syndrome
Time Factors
030204 cardiovascular system & hematology
Coronary Angiography
law.invention
03 medical and health sciences
Percutaneous Coronary Intervention
0302 clinical medicine
Randomized controlled trial
law
Cause of Death
Clinical endpoint
medicine
Creatine Kinase, MB Form
Humans
Prospective Studies
030212 general & internal medicine
Non-ST Elevated Myocardial Infarction
Aged
Aspirin
business.industry
ST elevation
Hazard ratio
Interim analysis
medicine.disease
Combined Modality Therapy
Fondaparinux
Area Under Curve
Anesthesia
Early Termination of Clinical Trials
Female
Cardiology and Cardiovascular Medicine
business
Medical Futility
Platelet Aggregation Inhibitors
Mace
Factor Xa Inhibitors
medicine.drug
- Language
- ISSN
- 0002-8703
Background: In intermediate- and high-risk non-ST elevated acute coronary syndrome (NSTE-ACS) patients, a routine invasive approach is recommended. The timing of coronary angiography remains controversial. To assess whether an immediate (